Fundamental Analysis of ITEOS THERAPEUTICS INC(NASDAQ:ITOS) stock

Fundamental Rating

Taking everything into account, ITOS scores 4 out of 10 in our fundamental rating. ITOS was compared to 588 industry peers in the Biotechnology industry. While ITOS has a great health rating, there are worries on its profitability. ITOS is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

ITOS had negative earnings in the past year.

In the past year ITOS has reported a negative cash flow from operations.

The reported net income has been mixed in the past 5 years: ITOS reported negative net income in multiple years.

ITOS had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

ITOS's Return On Assets of -16.87% is amongst the best of the industry. ITOS outperforms 85.32% of its industry peers.

ITOS has a better Return On Equity (-19.58%) than 87.88% of its industry peers.

		Industry Rank	Sector Rank
ROA	-16.87%
ROE	-19.58%
ROIC	N/A

ROA(3y)6.73%

ROA(5y)-15.75%

ROE(3y)11.27%

ROE(5y)-29.68%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ITOS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ITOS does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ITOS has been increased compared to 1 year ago.

Compared to 5 years ago, ITOS has more shares outstanding

ITOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

ITOS has an Altman-Z score of 2.97. This is not the best score and indicates that ITOS is in the grey zone with still only limited risk for bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 2.97, ITOS is in the better half of the industry, outperforming 75.43% of the companies in the same industry.

There is no outstanding debt for ITOS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	2.97

ROIC/WACCN/A

WACC9.31%

2.3 Liquidity

A Current Ratio of 13.76 indicates that ITOS has no problem at all paying its short term obligations.

ITOS has a better Current ratio (13.76) than 88.57% of its industry peers.

A Quick Ratio of 13.76 indicates that ITOS has no problem at all paying its short term obligations.

ITOS's Quick ratio of 13.76 is amongst the best of the industry. ITOS outperforms 88.74% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	13.76
Quick Ratio	13.76

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ITOS have decreased strongly by -223.68% in the last year.

Looking at the last year, ITOS shows a very negative growth in Revenue. The Revenue has decreased by -95.29% in the last year.

EPS 1Y (TTM)-223.68%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-255.22%

Revenue 1Y (TTM)-95.29%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2Q-100%

3.2 Future

The Earnings Per Share is expected to grow by 24.42% on average over the next years. This is a very strong growth

The Revenue is expected to grow by 102.50% on average over the next years. This is a very strong growth

EPS Next Y-54.08%

EPS Next 2Y-41.55%

EPS Next 3Y-6.76%

EPS Next 5Y24.42%

Revenue Next Year79.43%

Revenue Next 2Y-20.14%

Revenue Next 3Y130.76%

Revenue Next 5Y102.5%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ITOS. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ITOS. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ITOS's earnings are expected to decrease with -6.76% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-41.55%

EPS Next 3Y-6.76%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ITOS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ITEOS THERAPEUTICS INC

NASDAQ:ITOS (4/26/2024, 7:00:02 PM)

After market: 10.8 0 (0%)

10.8

+0.2 (+1.89%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap387.07M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-16.87%
ROE	-19.58%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.02

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	13.76
Quick Ratio	13.76
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-223.68%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-54.08%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-95.29%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ITEOS THERAPEUTICS INC (ITOS)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens